Price (delayed)
$19.13
Market cap
$2.17B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.93
Enterprise value
$2B
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective,
There are no recent dividends present for CBAY.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.